4D Molecular Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$13.49 -4.87%
VS HALOHalozyme Therapeutics, Inc.
$110.79 +0.98%
4D Molecular Therapeutics, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| FDMT | HALO | |
|---|---|---|
| Market Cap | $745.24 million | $12.45 billion |
| Revenue (TTM) | $92.01 million | — |
| Net Income (TTM) | $-179,175,000 | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| FDMT | HALO | |
|---|---|---|
| Price / Book | 1.83 | — |
| Price / Sales | 8.10 | — |
FDMT and HALO split the valuation factors evenly.
Profitability
| FDMT | HALO | |
|---|---|---|
| Net Margin | -194.74% | — |
| Return on Equity | -43.95% | — |
FDMT and HALO split the profitability factors evenly.
Risk & Sentiment
| FDMT | HALO | |
|---|---|---|
| Short Interest | 0.41% | 9.79% |
FDMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: FDMT overview, FDMT financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.